▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NexgenRx in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.37.
The current consensus among 0 polled investment analysts is to n/a stock in NexgenRx. This rating has held steady since December 2020, when it changed from a Hold consensus rating.
NexgenRx Inc. administers, adjudicates, and pays drug, dental, and other extended health-care claims for the beneficiaries of health benefit plans in Canada. It offers prescription drug claims; dental claims; and claims for extended health benefits, as well as provides a health care spending account that offers an amount of money to an individual to pay for health or dental benefits. The company also provides individual and aggregate stop loss products; medical emergency and travel assistance insurance services; administrative services, including the collection and payment of premiums for life and LTD coverage, as well as a suite of reporting tools; Web claims submission services; direct deposit services; and ancillary services. NexgenRx Inc. was founded in 2003 and is headquartered in Toronto, Canada.